The ENCePP Secretariat accepts no responsibility for the content of material and/or announcements in this section, including, without limitation, any error, omission or inaccuracy therein. If the announcement provides a link to a third-party website, please see the ENCePP Linking Policy.
COVID-19 pandemic response
|18/05/2021||Background incidence rates of thromboembolic events with thrombocytopenia from 6 Member States – first report from the study on natural history of coagulopathy and use of anti-thrombotic agents in COVID-19 patients and persons vaccinated against SARS-CoV-2|
ACCESS Updated background incidence rates (AESIs and thromboembolic events)
** All ACCESS background rate data are now available on the VAC4EU dashboard **
|19/03/2021||ACCESS Preliminary incidence rates of embolic and thrombotic events following immunisation with COVID-19 vaccines|
|08/03/2021||ACCESS Background incidence rates of adverse events of special interest (AESIs) for COVID-19 vaccines|